Innate and adaptive immune cells in the tumor microenvironment

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · see citing works

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · see citing works

Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria

Ivanov, I. I., Atarashi, K., Manel, N., Brodie, E. L., Shima, T., Karaoz, U., Wei, D., Goldfarb, K. C., Santee, C. A., Lynch, S. V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.033 · Cited by 4,554 · see citing works

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., Plaen, E. D., den Eynde, B. J. V., Knuth, A. K., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,548 · see citing works

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I. J., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,542 · see citing works

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397 · see citing works

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · see citing works

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · see citing works

Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer

Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · see citing works

<i>Batf3</i> Deficiency Reveals a Critical Role for CD8α ⁺ Dendritic Cells in Cytotoxic T Cell Immunity

Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081 · see citing works

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · see citing works

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · see citing works

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,678 · see citing works

Up-Regulation of PD-L1, IDO, and T _regs in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells

Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677 · see citing works

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647 · see citing works

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

Groh, V., Wu, J. D., Yee, C., & Spies, T. A. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,596 · see citing works

Gut-Residing Segmented Filamentous Bacteria Drive Autoimmune Arthritis via T Helper 17 Cells

Wu, H.-J., Ivanov, I. I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., Littman, D. R., Benoist, C., & Mathis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.001 · Cited by 1,577 · see citing works

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377 · see citing works

Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer

Mahmoud, S., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367 · see citing works

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285 · see citing works

Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells

Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192 · see citing works

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

Nagaraj, S., Gupta, K., Писарев, В. М., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J. P., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,176 · see citing works

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors

Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138 · see citing works

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α

Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · see citing works

Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment

Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · see citing works

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081 · see citing works

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,074 · see citing works

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells

Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,063 · see citing works

BRAF and RAS mutations in human lung cancer and melanoma.

Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,053 · see citing works

Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4

Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050 · see citing works

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009 · see citing works

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944 · see citing works

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

Zeng, J., See, A. P., Phallen, J., Jackson, C. M., Belcaid, Z., Ruzevick, J., Durham, N., Meyer, C., Harris, T. J., Albesiano, E., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.12.025 · Cited by 889 · see citing works

The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon–Dependent Innate and Adaptive Immunity

Burnette, B., Liang, H. L., Lee, Y., Chlewicki, L. K., Khodarev, N. N., Weichselbaum, R. R., Fu, Y., & Auh, S. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2820 · Cited by 883 · see citing works

Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma

Azimi, F., Scolyer, R. A., Rumcheva, P., Moncrieff, M. D., Murali, R., McCarthy, S. W., Saw, R. P. M., & Thompson, J. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8539 · Cited by 857 · see citing works

NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy

Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N. R., & Raulet, D. H. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.016 · Cited by 850 · see citing works

De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent

de Visser, K. E., Korets, L. V., & Coussens, L. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.014 · Cited by 826 · see citing works

Cancer classification using the Immunoscore: a worldwide task force

Galon, J., Pagès, F., Marincola, F. M., Angell, H. K., Thurin, M., Lugli, A., Zlobec, I., Berger, A., Bifulco, C. B., Botti, G., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-205 · Cited by 790 · see citing works

Interleukin (IL)-15 and IL-7 Jointly Regulate Homeostatic Proliferation of Memory Phenotype CD8+ Cells but Are Not Required for Memory Phenotype CD4+ Cells

Tan, J. T., Ernst, B., Kieper, W. C., LeRoy, E., Sprent, J., & Surh, C. D. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020066 · Cited by 790 · see citing works

An immune-active tumor microenvironment favors clinical response to ipilimumab

Ji, R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J. P., Alaparthy, S., Berman, D., Jure‐Kunkel, M., Siemers, N. O., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 771 · see citing works

Identification of a dendritic cell receptor that couples sensing of necrosis to immunity

Sancho, D., Joffre, O. P., Keller, A. M., Rogers, N. C., Martínez, D., Hernanz-Falcón, P., Rosewell, I., & Sousa, C. R. E. (2009) · Nature · doi:10.1038/nature07750 · Cited by 750 · see citing works

Gastrosplenic Fistula From Hodgkin's Lymphoma

Seib, C. D., Rocha, F. G., Hwang, D. G., & Shoji, B. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7695 · Cited by 736 · see citing works

NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence

Nielsen, M., Lundegaard, C., Blicher, T. H., Lamberth, K., Harndahl, M. N., Justesen, S. F. L., Røder, G., Peters, B., Sette, A., Lund, O., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000796 · Cited by 719 · see citing works

NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway

Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, L. C., Donaldson, D. D., Carbone, D. P., Paul, W. E., & Berzofsky, J. A. (2000) · Nature Immunology · doi:10.1038/82771 · Cited by 698 · see citing works

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

Ma, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Catani, J. P. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 698 · see citing works

Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells

Poulin, L. F., Salio, M., Griessinger, E., Anjos‐Afonso, F., Craciun, L., Chen, J., Keller, A. M., Joffre, O. P., Zelenay, S., Nye, E. L., et al. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20092618 · Cited by 667 · see citing works

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

Kreike, B., van Kouwenhove, M., Horlings, H. M., Weigelt, B., Peterse, H. L., Bartelink, H. G. M. M., & van de Vijver, M. J. (2007) · Breast Cancer Research · doi:10.1186/bcr1771 · Cited by 613 · see citing works

A critical function for type I interferons in cancer immunoediting

Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C. D., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 611 · see citing works

Adoptive cell therapy for the treatment of patients with metastatic melanoma

Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 596 · see citing works

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M., Thomas, B. A., Rupar, M. J., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 549 · see citing works

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O’Brien-Jenkins, A., Gimotty, P. A., & Coukos, G. (2007) · Nature Medicine · doi:10.1038/nm1699 · Cited by 546 · see citing works

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534 · see citing works

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C. E., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 523 · see citing works

Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin

Sancho, D., Mourão‐Sá, D., Joffre, O. P., Schulz, O., Rogers, N. C., Pennington, D. J., Carlyle, J. R., & Sousa, C. R. E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34584 · Cited by 519 · see citing works

Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21

Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J., & Swartz, M. A. (2010) · Science · doi:10.1126/science.1185837 · Cited by 506 · see citing works

l -Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes

Rodrı́guez, P. C., Zea, A. H., DeSalvo, J., Culotta, K. S., Zabaleta, J., Quiceno, D. G., Ochoa, J. B., & Ochoa, A. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1232 · Cited by 494 · see citing works

The Indoleamine 2,3-Dioxygenase Pathway Is Essential for Human Plasmacytoid Dendritic Cell-Induced Adaptive T Regulatory Cell Generation

Chen, W., Liang, X., Peterson, A. J., Munn, D. H., & Blazar, B. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5396 · Cited by 453 · see citing works

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth

Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432 · see citing works

12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?

Messina, J. L., Fenstermacher, D. A., Eschrich, S., Qu, X., Berglund, A. E., Lloyd, M. C., Schell, M. J., Sondak, V. K., Weber, J. S., & Mulé, J. J. (2012) · Scientific Reports · doi:10.1038/srep00765 · Cited by 426 · see citing works

Tumor-Infiltrating γδ T Cells Suppress T and Dendritic Cell Function via Mechanisms Controlled by a Unique Toll-like Receptor Signaling Pathway

Peng, G., Wang, H. Y., Peng, W., Kiniwa, Y., Seo, K. H., & Wang, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.020 · Cited by 408 · see citing works

F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells

Ahrens, S., Zelenay, S., Sancho, D., Hanč, P., Kjær, S., Feest, C., Fletcher, G., Durkin, C. H., Postigo, A. A., Skehel, M. J., et al. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.008 · Cited by 393 · see citing works

Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma

Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P. J., Mottram, P. J., Curiel, T. J., Lange, A., & Zou, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4043 · Cited by 379 · see citing works

Type I interferon response and innate immune sensing of cancer

Fuertes, M. B., Woo, S.-R., Burnett, B., Fu, Y.-X., & Gajewski, T. F. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.10.004 · Cited by 375 · see citing works

Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.

Quatromoni, J. G., & Eruslanov, E. B. (2012) · Europe PMC (PubMed Central) · Cited by 360 · see citing works

Priming of naive T cells inside tumors leads to eradication of established tumors

Yu, P., Lee, Y., Liu, W., Chin, R., Wang, J. H., Wang, Y., Schietinger, A., Philip, M., Schreiber, H. W., & Fu, Y. (2004) · Nature Immunology · doi:10.1038/ni1029 · Cited by 356 · see citing works

Impaired IFN-α Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression

Sisirak, V., Faget, J., Gobert, M., Goutagny, N., Vey, N., Treilleux, I., Renaudineau, S., Poyet, G., Labidi‐Galy, S. I., Goddard‐Léon, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3468 · Cited by 346 · see citing works

An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium

Johnson, L. A., Clasper, S., Holt, A. P., Lalor, P. F., Baban, D., & Jackson, D. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051759 · Cited by 346 · see citing works

NKG2D function protects the host from tumor initiation

Smyth, M. J., Swann, J. B., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 344 · see citing works

CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation

Rakhra, K., Bachireddy, P., Zabuawala, T., Zeiser, R., Xu, L., Kopelman, A., Fan, A. C., Yang, Q., Braunstein, L., Crosby, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.002 · Cited by 339 · see citing works

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

Delahaye, N. F., Rusakiewicz, S., Martins, I., Menard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2366 · Cited by 338 · see citing works

CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients

Rech, A. J., Mick, R., Martin, S., Recio, A., Aqui, N. A., Powell, D. J., Colligon, T. A., Trosko, J. A., Leinbach, L. I., Pletcher, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003330 · Cited by 335 · see citing works

Plasmacytoid dendritic cells induce NK cell–dependent, tumor antigen–specific T cell cross-priming and tumor regression in mice

Liu, C., Lou, Y., Lizee, G. A., Qin, H., Liu, S., Rabinovich, B. A., Kim, G. J., Wang, Y.-H., Ye, Y., Sikora, A. G., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33583 · Cited by 317 · see citing works

β-Catenin induces immortalization of melanocytes by suppressing p16 INK4a expression and cooperates with N-Ras in melanoma developmentPreprint

Delmas, V., Beermann, F., Martinozzi, S., Carreira, S., Ackermann, J., Kumasaka, M. Y., Denat, L., GOODALL, J. C., Luciani, F., Virós, A., et al. (2007) · Genes & Development · doi:10.1101/gad.450107 · Cited by 312 · see citing works

Prevention of T Cell Anergy by Signaling Through the γ c Chain of the IL-2 Receptor

Boussiotis, V. A., Barber, D. L., Nakarai, T., Freeman, G. J., Gribben, J. G., Bernstein, G. M., D’Andrea, A. D., Ritz, J., & Nadler, L. M. (1994) · Science · doi:10.1126/science.7973657 · Cited by 307 · see citing works

Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?

Bui, J. D., & Schreiber, R. D. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.001 · Cited by 304 · see citing works

Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors

Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, Á., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 304 · see citing works

Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma

Attia, P., Maker, A. V., Haworth, L. R., Rogers-Freezer, L. J., & Rosenberg, S. A. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175468.19742.10 · Cited by 286 · see citing works

Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation

Zhou, X., Gimm, O., Hampel, H., Niemann, T. H., Walker, M. J., & Eng, C. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64627-5 · Cited by 278 · see citing works

Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer

Narra, K., Mullins, S., Lee, H.-O., Strzemkowski-Brun, B., Magalong, K., Christiansen, V. J., McKee, P. A., Egleston, B. L., Cohen, S. J., Weiner, L. M., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.11.4874 · Cited by 276 · see citing works

The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice

Zelenay, S., Keller, A. M., Whitney, P. G., Schraml, B. U., Deddouche, S., Rogers, N. C., Schulz, O., Sancho, D., & Sousa, C. R. E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60644 · Cited by 272 · see citing works

DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues

Poulin, L. F., Reyal, Y., Uronen‐Hansson, H., Schraml, B. U., Sancho, D., MURPHY, K. M. M., Håkansson, U., Moita, L. F., Agace, W. W., Bonnet, D. A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-406967 · Cited by 251 · see citing works

Gene Signature in Melanoma Associated With Clinical Activity: A Potential Clue to Unlock Cancer Immunotherapy

Gajewski, T. F., Louahed, J., & Brichard, V. G. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eacbd8 · Cited by 250 · see citing works

The WNT/Beta-catenin pathway in melanoma

Larue, L. (2006) · Frontiers in bioscience · doi:10.2741/1831 · Cited by 250 · see citing works

Cytoplasmic DNA innate immune pathways

Barber, G. N. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01051.x · Cited by 247 · see citing works

A unique tumor antigen produced by a single amino acid substitution

Monach, P. A., Meredith, S. C., Siegel, C., & Schreiber, H. W. (1995) · Immunity · doi:10.1016/1074-7613(95)90078-0 · Cited by 242 · see citing works

Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment

Gajewski, T. F. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0892 · Cited by 230 · see citing works

Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy

Sportès, C., Babb, R. R., Krumlauf, M., Hakim, F. T., Steinberg, S. M., Chow, C. K., Brown, M. R., Fleisher, T. A., Noël, P., Marić, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1303 · Cited by 227 · see citing works

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma

Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N., & Tanabe, K. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1021-7 · Cited by 203 · see citing works

High endothelial venules (HEVs) in human melanoma lesions

Martinet, L., Guellec, S. L., Filleron, T., Lamant, L., Meyer, N., Rochaix, P., Garrido, I., & Girard, J. (2012) · OncoImmunology · doi:10.4161/onci.20492 · Cited by 195 · see citing works

Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells

Daniel, D., Meyer-Morse, N., Bergsland, E. K., Dehne, K., Coussens, L. M., & Hanahan, D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021047 · Cited by 180 · see citing works

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Mortarini, R., Piris, A., Maurichi, A., Molla, A., Bersani, I., Bono, A. V., Bartoli, C., Santinami, M., Lombardo, C., Ravagnani, F., et al. (2003) · PubMed · Cited by 177 · see citing works

Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells.

Singh, S., Ross, S. R., Acena, M., Rowley, D. A., & Schreiber, H. W. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.1.139 · Cited by 170 · see citing works

Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

Jinushi, M., Hodi, F. S., & Dranoff, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603503103 · Cited by 168 · see citing works

Radiation-Induced Equilibrium Is a Balance between Tumor Cell Proliferation and T Cell–Mediated Killing

Liang, H. L., Deng, L., Chmura, S. J., Burnette, B., Liadis, N., Darga, T. E., Beckett, M. A., Lingen, M. W., Witt, M. E., Weichselbaum, R. R., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202612 · Cited by 165 · see citing works

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

Richter, J. R., Neparidze, N., Zhang, L., Nair, S., Monesmith, T., Sundaram, R. K., Miesowicz, F., Dhodapkar, K. M., & Dhodapkar, M. V. (2012) · Blood · doi:10.1182/blood-2012-06-435503 · Cited by 164 · see citing works

Characterization of Tumor Reactivity of Human Vγ9Vδ2 γδ T Cells In Vitro and in SCID Mice In Vivo

Kabelitz, D., Wesch, D., Pitters, E., & Zöller, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6767 · Cited by 163 · see citing works

Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms

Demoulin, S., Herfs, M. F., Delvenne, P., & Hubert, P. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0812397 · Cited by 162 · see citing works

Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model

Wen, Y., Wang, C., Ma, T., Li, Z., Zhou, L., Mu, B., Leng, F., Shi, H., Li, Y., & Wei, Y. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01695.x · Cited by 161 · see citing works

Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity

Mattarollo, S. R., Kenna, T., Nieda, M., & Nicol, A. J. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0279-2 · Cited by 160 · see citing works

GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development

Brichard, V. G., & Lejeune, D. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.038 · Cited by 159 · see citing works

Transient T cell depletion causes regression of melanoma metastases

Rasku, M. A., Clem, A. L., Telang, S., Taft, B. S., Gettings, K. F., Gragg, H., Cramer, D. E., Lear, S. C., McMasters, K. M., Miller, D. M., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-12 · Cited by 158 · see citing works

Chimeric NK-receptor–bearing T cells mediate antitumor immunotherapy

Zhang, T., Lemoi, B. A., & Sentman, C. L. (2005) · Blood · doi:10.1182/blood-2004-11-4365 · Cited by 155 · see citing works

New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site

Appay, V., Jandus, C., Voelter, V., Reynard, S., Coupland, S. E., Rimoldi, D., Líénard, D., Guillaume, P., Krieg, A. Μ., Cerottini, J., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1670 · Cited by 150 · see citing works

Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity

Engels, B., Engelhard, V. H., Sidney, J., Sette, A., Binder, D. C., Liu, R. B., Kranz, D. M., Meredith, S. C., Rowley, D. A., & Schreiber, H. W. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.018 · Cited by 149 · see citing works

IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk

Strasly, M., Cavallo, F., Geuna, M., Mitola, S. M. F., Colombo, M. P., Forni, G., & Bussolino, F. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.6.3890 · Cited by 148 · see citing works

Redirecting αβT cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor

Marcu‐Malina, V., Heijhuurs, S., van Buuren, M., Hartkamp, L. M., Strand, S., Sebestyén, Z., Scholten, K. B. J., Martens, A. C., & Kuball, J. H. E. (2011) · Blood · doi:10.1182/blood-2010-12-325993 · Cited by 144 · see citing works

Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites

Harlin, H., Kuna, T. V., Peterson, A., Meng, Y., & Gajewski, T. F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0118-2 · Cited by 143 · see citing works

Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma

Kunz, M., Toksoy, A., Goebeler, M., Engelhardt, E., Br�cker, E.-B., & Gillitzer, R. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199912)189:4 · Cited by 140 · see citing works

Plasmacytoid Dendritic Cells Synergize with Myeloid Dendritic Cells in the Induction of Antigen-Specific Antitumor Immune Responses

Lou, Y., Liu, C., Kim, G. J., Liu, Y., Hwu, P., & Wang, G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1534 · Cited by 134 · see citing works

Stat3 Activity in Melanoma Cells Affects Migration of Immune Effector Cells and Nitric Oxide-Mediated Antitumor Effects

Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3925 · Cited by 131 · see citing works

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

Petrella, T. M., Tozer, R. G., Bélanger, K., Savage, K. J. J., Wong, R., Smylie, M., Kamel‐Reid, S., Tron, V. A., Chen, B. E., Hunder, N. N. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.0655 · Cited by 126 · see citing works

RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry

Jung, H., Hsiung, B., Pestal, K., Procyk, E., & Raulet, D. H. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120565 · Cited by 123 · see citing works

Type I natural killer T cells suppress tumors caused by p53 loss in mice

Swann, J. B., Uldrich, A. P., van Dommelen, S. L. H., Sharkey, J., Murray, W. K., Godfrey, D. I., & Smyth, M. J. (2009) · Blood · doi:10.1182/blood-2009-01-198564 · Cited by 116 · see citing works

Selective Inhibition of Fibroblast Activation Protein Protease Based on Dipeptide Substrate Specificity

Edosada, C. Y., Quan, C. L., Wiesmann, C., Tran, T., Sutherlin, D., Reynolds, M., Elliott, J. M., Raab, H. E., Fairbrother, W. J., & Wolf, B. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511112200 · Cited by 114 · see citing works

From defined human tumor antigens to effective immunization?

Boon, T., Gajewski, T. F., & Coulie, P. G. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80149-9 · Cited by 113 · see citing works

Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma

Massi, D., Tarantini, F., Franchi, A., Paglierani, M., Serio, C. D., Pellerito, S., Leoncini, G., Cirino, G., Geppetti, P., & Santucci, M. (2005) · Modern Pathology · doi:10.1038/modpathol.3800526 · Cited by 101 · see citing works

Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment

Barber, A. E., Rynda, A., & Sentman, C. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902000 · Cited by 101 · see citing works

Chemotherapy-Induced Genotoxic Stress Promotes Sensitivity to Natural Killer Cell Cytotoxicity by Enabling Missing-Self Recognition

Fine, J. H., Chen, P., Mesci, A., Allan, D., Gasser, S., Raulet, D. H., & Carlyle, J. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1316 · Cited by 100 · see citing works

Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection

Brown, I. E., Blank, C., Kline, J., Kacha, A. K., & Gajewski, T. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4521 · Cited by 91 · see citing works

Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma

Kline, J. P., Brown, I. E., Zha, Y.-Y., Blank, C. U., Strickler, J. H., Wouters, H., Zhang, L., & Gajewski, T. F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4696 · Cited by 89 · see citing works

Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy

Ugurel, S., Schrama, D., Keller, G., Schadendorf, D., Bröcker, E.-B., Houben, R., Zapatka, M., Fink, W., Kaufman, H. L., & Becker, J. C. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0407-z · Cited by 88 · see citing works

Functional differences between low- and high-affinity CD8+T cells in the tumor environment

Bos, R., Marquardt, K., Cheung, J., & Sherman, L. A. (2012) · OncoImmunology · doi:10.4161/onci.21285 · Cited by 80 · see citing works

Targeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases

Yü, P., Lee, Y., Wang, Y., Liu, X., Auh, S. L., Gajewski, T. F., Schreiber, H. W., You, Z., Kaynor, C., Wang, X., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1960 · Cited by 79 · see citing works

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Telang, S., Rasku, M. A., Clem, A. L., Carter, K., Klarer, A. C., Badger, W. R., Milam, R. A., Rai, S. N., Pan, J., Gragg, H., et al. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-515 · Cited by 76 · see citing works

Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma

Zhang, B., Zhang, Y., Bowerman, N. A., Schietinger, A., Fu, Y., Kranz, D. M., Rowley, D. A., & Schreiber, H. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5324 · Cited by 73 · see citing works

Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors

Russell, J. P., Shinohara, S., Melillo, R. M., Castellone, M. D., Santoro, M. M., & Rothstein, J. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206759 · Cited by 68 · see citing works

Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma

Dengel, L. T., Norrod, A. G., Gregory, B. L., Clancy‐Thompson, E., Burdick, M. D., Strieter, R. M., Slingluff, C. L., & Mullins, D. W. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fb045d · Cited by 68 · see citing works

Activated Stat-3 in Melanoma

Messina, J. L., Yu, H., Riker, A. I., Münster, P. N., Jove, R., & DAUD, A. I. (2008) · Cancer Control · doi:10.1177/107327480801500302 · Cited by 67 · see citing works

Local IL-21 Promotes the Therapeutic Activity of Effector T cells by Decreasing Regulatory T Cells Within the Tumor Microenvironment

Kim‐Schulze, S., Kim, H. S., Fan, Q., Kim, D. W., & Kaufman, H. L. (2008) · Molecular Therapy · doi:10.1038/mt.2008.249 · Cited by 66 · see citing works

The confluence of radiotherapy and immunotherapy

Burnette, B., Fu, Y., & Weichselbaum, R. R. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00143 · Cited by 65 · see citing works

IFN-γ-Producing Human Invariant NKT Cells Promote Tumor-Associated Antigen-Specific Cytotoxic T Cell Responses

Moreno, M., Molling, J. W., von Mensdorff‐Pouilly, S., Verheijen, R. H. M., Hooijberg, E., Kramer, D., Reurs, A. W., van den Eertwegh, A. J. M., Blomberg, B. M. E. V., Scheper, R. J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2446 · Cited by 55 · see citing works

Densely Granulated Murine NK Cells Eradicate Large Solid Tumors

Liu, R. B., Engels, B., Arina, A., Schreiber, K., Hyjek, E. M., Schietinger, A., Binder, D. C., Butz, E. A., Krausz, T. N., Rowley, D. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3208 · Cited by 54 · see citing works

Role of γδ T Cells in α-Galactosylceramide–Mediated Immunity

Paget, C., Chow, M. T., Duret, H., Mattarollo, S. R., & Smyth, M. J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103582 · Cited by 53 · see citing works

Mechanisms of the Antitumor Activity of Human Vγ9Vδ2 T Cells in Combination With Zoledronic Acid in a Preclinical Model of Neuroblastoma

Carlo, E. D., Bocca, P., Emionite, L., Cilli, M., Cipollone, G., Morandi, F., Raffaghello, L., Pistoia, V., & Prigione, I. (2013) · Molecular Therapy · doi:10.1038/mt.2013.38 · Cited by 52 · see citing works

Innate immune sensing of cancer: clues from an identified role for type I IFNs

Gajewski, T. F., Fuertes, M. B., & Woo, S. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1305-6 · Cited by 50 · see citing works

Egr2-dependent gene expression profiling and ChIP-Seq reveal novel biologic targets in T cell anergy

Zheng, Y., Zha, Y., Spaapen, R. M., Mathew, R. S., Barr, K., Bendelac, A. S., & Gajewski, T. F. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.03.006 · Cited by 45 · see citing works

IRF5 gene polymorphisms in melanoma

Uccellini, L., Giorgi, V. D., Zhao, Y., Tumaini, B., Erdenebileg, N., Dudley, M. E., Tomei, S., Bedognetti, D., Ascierto, M. L., Liu, Q., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-170 · Cited by 41 · see citing works

Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles

Mortarini, R., Scarito, A., Nonaka, D., Zanon, M., Bersani, I., Montaldi, E., Pennacchioli, E., Patuzzo, R., Santinami, M., & Anichini, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3239 · Cited by 39 · see citing works

A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response

Sullivan, R. J., Hoshida, Y., Brunet, J.-P., Tahan, S. R., Aldridge, J., Kwabi, C., Gardiner, E., McDermott, D. F., Golub, T. R., & Atkins, M. B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.9003 · Cited by 39 · see citing works

Vaccination with Antigen-Transfected, NKT Cell Ligand–Loaded, Human Cells Elicits Robust In Situ Immune Responses by Dendritic Cells

Shimizu, K., Mizuno, T., Shinga, J., Asakura, M., Kakimi, K., Ishii, Y., Masuda, K., Maeda, T., Sugahara, H., Sato, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0759 · Cited by 37 · see citing works

NK Cells and γδ T Cells Mediate Resistance to Polyomavirus–Induced Tumors

Mishra, R., Chen, A. T., Welsh, R. M., & Szomolanyi‐Tsuda, E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000924 · Cited by 36 · see citing works

Critical Role of CD11a (LFA-1) in Therapeutic Efficacy of Systemically Transferred Antitumor Effector T Cells

Mukai, S., Kagamu, H., Shu, S., & Plautz, G. E. (1999) · Cellular Immunology · doi:10.1006/cimm.1998.1439 · Cited by 33 · see citing works

Oncoprotein Signaling Mediates Tumor-Specific Inflammation and Enhances Tumor Progression

Pufnock, J., & Rothstein, J. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801284 · Cited by 25 · see citing works

Recognition of Shared Melanoma Antigens by Human Tumor-Infiltrating Lymphocytes

Topalian, S. L., Horn, S. S., Kawakami, Y., Mancini, M., Schwartzentruber, D. J., Zakut, R., & Rosenberg, S. A. (1992) · Journal of Immunotherapy · doi:10.1097/00002371-199210000-00013 · Cited by 23 · see citing works

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179 · see citing works

Tumor-Associated Macrophages: From Mechanisms to Therapy

Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · see citing works

New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer

Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876 · see citing works

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,414 · see citing works

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., den Eynden, G. V., Baehner, F. L., Penault-Llorca, F. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,142 · see citing works

Inflammation and tumor progression: signaling pathways and targeted intervention

Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,907 · see citing works

Macrophage Polarization

Murray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981 · see citing works

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,382 · see citing works

Immunotherapy in colorectal cancer: Rationale, challenges and potential

Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954 · see citing works

Targeting macrophages: therapeutic approaches in cancer

Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,057 · see citing works

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857 · see citing works

Pattern recognition receptors in health and diseases

Li, D., & Wu, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00687-0 · Cited by 1,830 · see citing works

Nanotechnology for Multimodal Synergistic Cancer Therapy

Fan, W., Yung, B. C., Huang, P., & Chen, X. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,804 · see citing works

Cytotoxic CD8+ T cells in cancer and cancer immunotherapy

Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687 · see citing works

NRF2 and the Hallmarks of Cancer

Rojo de la Vega, M., Chapman, E., & Zhang, D. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.022 · Cited by 1,672 · see citing works

Comprehensive review of targeted therapy for colorectal cancer

Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687 · see citing works

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma

Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · see citing works

Oncolytic viruses: a new class of immunotherapy drugs

Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,651 · see citing works

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635 · see citing works

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape

Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471 · see citing works

Mechanisms of resistance to immune checkpoint inhibitors

Jenkins, R. W., Barbie, D. A., & Flaherty, K. T. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.434 · Cited by 1,383 · see citing works

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

Davoli, T., Uno, H., Wooten, E. C., & Elledge, S. J. (2017) · Science · doi:10.1126/science.aaf8399 · Cited by 1,325 · see citing works

Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy

Pitt, J. M., Marabelle, A., Eggermont, A. M. M., Soria, J., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,344 · see citing works

STING: infection, inflammation and cancer.

Barber, G. N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3921 · Cited by 1,313 · see citing works

Tumor Microenvironment

Arneth, B. M. (2019) · Medicina · doi:10.3390/medicina56010015 · Cited by 1,339 · see citing works

T Cell Dysfunction in Cancer

Thommen, D. S., & Schumacher, T. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.012 · Cited by 1,304 · see citing works

Type I interferons in anticancer immunity

Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305 · see citing works

Targeted agents and immunotherapies: optimizing outcomes in melanoma

Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,243 · see citing works

Therapeutic cancer vaccines

Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,182 · see citing works

The lung microenvironment: an important regulator of tumour growth and metastasis

Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B. M., McGraw, T. E., & Mittal, V. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,147 · see citing works

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N. C., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,123 · see citing works

Targeting the tumour stroma to improve cancer therapy

Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084 · see citing works

Cold Tumors: A Therapeutic Challenge for Immunotherapy

Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau‐Guilemond, J., Valsesia‐Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,102 · see citing works

Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer

Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15081 · Cited by 992 · see citing works

Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front

Schürch, C. M., Bhate, S. S., Barlow, G. L., Phillips, D. J., Noti, L., Zlobec, I., Chu, P., Black, S., Demeter, J., McIlwain, D. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.005 · Cited by 1,058 · see citing works

CD8+ T cell differentiation and dysfunction in cancer

Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052 · see citing works

Tumour-associated neutrophils in patients with cancer

Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,044 · see citing works

Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma

Roberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,030 · see citing works

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability

Ma, X., Xiao, L., Liu, L., Ye, L., Pan, S., Bi, E., Wang, Q., Yang, M., Qian, J., & Yi, Q. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.015 · Cited by 1,022 · see citing works

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078 · see citing works

ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy

Miao, Y., Zhang, Q., Lei, Q., Luo, M., Xie, G., Wang, H., & Guo, A. (2020) · Advanced Science · doi:10.1002/advs.201902880 · Cited by 962 · see citing works

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures

Şenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Allen, E. M. V., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E. N., Luna, A., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1092-z · Cited by 949 · see citing works

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Pfirschke, C., Engblom, C., Rickelt, S., Cortez‐Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 944 · see citing works

Metabolic Interactions in the Tumor Microenvironment

Lyssiotis, C. A., & Kimmelman, A. C. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.003 · Cited by 853 · see citing works

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

Henau, O. D., Rausch, M. P., Winkler, D. A., Campesato, L. F., Liu, C., Hirschhorn-Cymerman, D., Budhu, S., Ghosh, A., Pink, M. M., Tchaicha, J. H., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 862 · see citing works

A guiding map for inflammation

Netea, M. G., Balkwill, F., Chonchol, M., Cominelli, F., Donath, M. Y., Giamarellos-Bourboulis, E. J., Golenbock, D., Gresnigt, M. S., Heneka, M. T., Hoffman, H. M., et al. (2017) · Nature Immunology · doi:10.1038/ni.3790 · Cited by 831 · see citing works

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

Allen, E., Jabouille, A., Rivera, L. B., Lodewijckx, I., Missiaen, R., Steri, V., Feyen, K., Tawney, J., Hanahan, D., Michael, I. P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9679 · Cited by 820 · see citing works

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

Hendry, S. A., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., de Vijver, K. K. V., Estrada, M. V., Ericsson, P. I. G., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 803 · see citing works

Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer

Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773 · see citing works

Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer

Zhang, Y., Chen, H., Mo, H., Hu, X., Gao, R., Zhao, Y., Liu, B., Niu, L., Sun, X., Yu, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.010 · Cited by 783 · see citing works

Role of Local Radiation Therapy in Cancer Immunotherapy

Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 780 · see citing works

Tumor microenvironment: Sanctuary of the devil

Hui, L., & Chen, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.039 · Cited by 776 · see citing works

Genetics and biology of prostate cancerPreprint

Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 758 · see citing works

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

He, C., Duan, X., Guo, N., Chan, C., Poon, C. J., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 755 · see citing works

In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform

Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., & Searson, P. C. (2016) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00012 · Cited by 754 · see citing works

WNT/β-catenin pathway activation correlates with immune exclusion across human cancers

Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722 · see citing works

De-novo and acquired resistance to immune checkpoint targeting

Syn, N. L. X., Teng, M. W. L., Mok, T. S. K., & Soo, R. A. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30607-1 · Cited by 742 · see citing works

Brain immunology and immunotherapy in brain tumours

Sampson, J. H., Gunn, M. D., Fecci, P. E., & Ashley, D. M. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0224-7 · Cited by 733 · see citing works

Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity

He, Y., Fu, L., Li, Y., Wang, W., Gong, M., Zhang, J., Dong, X., Huang, J., Wang, Q., Mackay, C. R., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.002 · Cited by 729 · see citing works

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 723 · see citing works

Impact of Obesity and Metabolic Syndrome on Immunity

Andersen, C. J., Murphy, K. E., & Fernandez, M. L. (2016) · Advances in Nutrition · doi:10.3945/an.115.010207 · Cited by 701 · see citing works

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

Hendry, S. A., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., de Vijver, K. K. V., Estrada, M. V., Ericsson, P. I. G., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000162 · Cited by 707 · see citing works

Wnt/beta-catenin pathway: modulating anticancer immune response

Pai, S. G., Carneiro, B. A., Mota, J. M., da Costa, R. B., Leite, C. A., Barroso‐Sousa, R., Kaplan, J. B., Chae, Y. K., & Giles, F. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0471-6 · Cited by 712 · see citing works

Cold and hot tumors: from molecular mechanisms to targeted therapy

Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 751 · see citing works

Integrating oncolytic viruses in combination cancer immunotherapy

Bommareddy, P. K., Shettigar, M., & Kaufman, H. L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0014-6 · Cited by 704 · see citing works

The two faces of IL-6 in the tumor microenvironment

Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.008 · Cited by 693 · see citing works

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

Wang, J., Sun, J., Liu, L. N., Flies, D. B., Nie, X., Toki, M. I., Zhang, J., Song, C. C., Zarr, M. A., Zhou, X., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0374-x · Cited by 676 · see citing works

In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy

Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669 · see citing works

Notch Signaling in the Tumor Microenvironment

Meurette, O., & Mehlen, P. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.009 · Cited by 680 · see citing works

Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?

Fares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P., & Hu‐Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 648 · see citing works

Multi-omic machine learning predictor of breast cancer therapy response

Sammut, S.-J., Crispin-Ortuzar, M., Chin, S.-F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S.-J., Abraham, J. E., et al. (2022) · Nature · doi:10.1038/s41586-021-04278-5 · Cited by 654 · see citing works

Nanocatalytic Tumor Therapy by Biomimetic Dual Inorganic Nanozyme‐Catalyzed Cascade Reaction

Gao, S., Lin, H., Zhang, H., Yao, H., Chen, Y., & Shi, J. (2018) · Advanced Science · doi:10.1002/advs.201801733 · Cited by 645 · see citing works

Diverging inflammasome signals in tumorigenesis and potential targeting

Karki, R., & Kanneganti, T. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0123-y · Cited by 641 · see citing works

Engineering CAR-T Cells for Next-Generation Cancer Therapy

Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 644 · see citing works

Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells

Zheng, P., Chen, L., Yuan, X., Luo, Q., Liu, Y., Xie, G., Ma, Y., & Shen, L. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0528-y · Cited by 630 · see citing works

Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer

Deepak, K. G. K., Vempati, R. K., Nagaraju, G. P., Dasari, V. R., Nagini, S., Rao, D. N., & Malla, R. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104683 · Cited by 618 · see citing works

The extracellular matrix in tumor progression and metastasis

Eble, J. A., & Niland, S. (2019) · Clinical &amp; Experimental Metastasis · doi:10.1007/s10585-019-09966-1 · Cited by 613 · see citing works

Exosomes and their roles in immune regulation and cancer

Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.02.009 · Cited by 608 · see citing works

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602 · see citing works

The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions

Lei, G., Zhuang, L., & Gan, B. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.011 · Cited by 615 · see citing works

Innate Immune Recognition of Cancer

Woo, S., Corrales, L. P., & Gajewski, T. F. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112043 · Cited by 569 · see citing works

Advances in cancer immunotherapy 2019 – latest trends

Krüger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schlößer, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 560 · see citing works

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis

Shen, X., & Zhao, B. (2018) · BMJ · doi:10.1136/bmj.k3529 · Cited by 559 · see citing works

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552 · see citing works

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525 · see citing works

In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy

Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 528 · see citing works

Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies

Xie, J., Wang, Y., Choi, W., Jangili, P., Ge, Y., Xu, Y., Kang, J., Liu, L., Zhang, B., Xie, Z., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01370f · Cited by 526 · see citing works

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 524 · see citing works

Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy

Angelova, M., Charoentong, P., Hackl, H., Fischer, M. L., Snajder, R., Krogsdam, A., Waldner, M. J., Bindea, G., Mlecnik, B., Galon, J., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0620-6 · Cited by 521 · see citing works

Optimizing oncolytic virotherapy in cancer treatment

Harrington, K. J., Freeman, D. J., Kelly, E. J., Harper, J. A., & Soria, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 523 · see citing works

TGFβ is a master regulator of radiation therapy-induced antitumor immunity

Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514 · see citing works

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting

Chaudhary, B., & Elkord, E. (2016) · Vaccines · doi:10.3390/vaccines4030028 · Cited by 516 · see citing works

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints

Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512 · see citing works

Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression

Niland, S., Riscanevo, A. X., & Eble, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010146 · Cited by 528 · see citing works

The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors

Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506 · see citing works

Type I Interferon in Chronic Virus Infection and Cancer

Snell, L. M., McGaha, T. L., & Brooks, D. G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.05.005 · Cited by 490 · see citing works

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity

Fu, W., Lei, C., Liu, S., Cui, Y., Wang, C., Qian, K., Li, T., Shen, Y., Fan, X., Lin, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12321-3 · Cited by 504 · see citing works

Tumor and Host Factors Regulating Anti-tumor Immunity and Immunotherapy Efficacy

Gajewski, T. F. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz326 · Cited by 1 · see citing works

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment

Gajewski, T. F., Corrales, L. P., Williams, J. B., Horton, B. L., Sivan, A., & Spranger, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_2 · Cited by 275 · see citing works

Innate Immune Sensing in Anti-Tumor Immunity and Cancer Immunotherapy

Gajewski, T. F. (2016) · Blood · doi:10.1182/blood.v128.22.sci-27.sci-27 · Cited by 1 · see citing works

The tumor microenvironment and its role in promoting tumor growth

Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376 · see citing works

Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment

Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 292 · see citing works